Advertisement

Search Results

Advertisement



Your search for The A matches 33023 pages

Showing 8451 - 8500


colorectal cancer

Study Examines Link Between in Utero Events and Risk of Colorectal Cancer in Adult Offspring

Infants whose mothers were obese during pregnancy may have a heightened risk of developing colorectal cancer later in life, according to new research published by Murphy et al in the journal Gut. Obesity is already a well-established risk factor for colorectal cancer, and several studies suggest...

bladder cancer

Addition of ATR Inhibitor Berzosertib to Cisplatin/Gemcitabine in Metastatic Urothelial Carcinoma

In a phase II trial reported in JAMA Oncology, Sumanta K. Pal, MD, FASCO, and colleagues found that the addition of the ATR inhibitor berzosertib to cisplatin/gemcitabine provided no benefit in patients with metastatic urothelial carcinoma. The triplet did not prolong progression-free survival, and ...

gynecologic cancers

Inguinofemoral Radiotherapy vs Inguinofemoral Lymphadenectomy for Patients With Vulvar Cancer and Sentinel Node Metastasis

In the phase II GROINSS-V II study reported in the Journal of Clinical Oncology, Oonk et al found that inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy in women with early-stage vulvar cancer and sentinel node micrometastasis but was associated with a higher...

breast cancer
global cancer care

Global Breast Cancer Survival: Estimated Impact of Scaling Up Access to Treatment/Imaging Modalities and Quality of Care

In a study reported in The Lancet Oncology, Ward et al estimated the improvements in global overall survival for female breast cancer that could be achieved via increased availability of treatment and imaging modalities, as well as improvements in quality of care. Study Details The study used a...

gastroesophageal cancer
immunotherapy

Addition of Pembrolizumab to Chemotherapy for the First-Line Treatment of Advanced Esophageal Cancer: KEYNOTE-590

As reported in The Lancet by Sun et al, the phase III KEYNOTE-590 trial showed that the addition of first-line pembrolizumab to chemotherapy resulted in improved overall and progression-free survival in patients with advanced esophageal and Siewert type 1 gastroesophageal junction (GEJ) cancers....

skin cancer

Are Triplets Necessary for BRAF-Mutated Melanoma?

Where does triplet therapy fit in the treatment of patients with stage IV BRAF-mutated melanoma? Is there strong evidence for combining a BRAF inhibitor, MEK inhibitor, and checkpoint inhibitor? Ragini Kudchadkar, MD, Chair of the Protocol Review and Monitoring Committee at Winship Cancer Institute ...

cns cancers

Cross-Sectional Survey Reveals Disparities in Care of Patients With Brain Metastases

A cross-sectional survey of patients, caregivers, and physicians on the diagnosis and treatment of brain metastases, conducted by the American Brain Tumor Association (ABTA) as part of its Metastatic Brain Tumor Initiative, revealed disparities in practice patterns and communication around...

lung cancer
immunotherapy

Study Highlights Gaps Between Lung Cancer Treatment Recommendations and Real-World Use of Durvalumab

A recent study published by Ronden et al in JTO Clinical and Research Reports highlights the gap between treatment guidelines and real-world care with the monoclonal antibody durvalumab for patients with non–small cell lung cancer. Researchers studied treatment decision-making by three Dutch...

leukemia
lymphoma
covid-19

Study Explores Relationship Between Anti-CD20 Therapy and Reduced Responses to mRNA COVID-19 Vaccines

Patients with lymphoma or other lymphoid cancers should continue to take steps to protect themselves from COVID-19 even if they have been vaccinated against the disease, a new study by Jennifer Crombie, MD, and colleagues published in Blood Advances suggests. The study found that patients who had...

lung cancer

First-Line Veliparib Plus Platinum-Based Chemotherapy in Current Smokers With Advanced Squamous Cell NSCLC

In a phase III trial reported in the Journal of Clinical Oncology, Suresh S. Ramalingam, MD, and colleagues found that the addition of the poly (ADP-ribose) polymerase inhibitor veliparib to platinum-based chemotherapy did not improve overall survival in current smokers with previously untreated...

breast cancer
symptom management

Pharmacologic Cardioprotection in Women With Nonmetastatic Breast Cancer Receiving Anthracycline-Based Chemotherapy

In an interim analysis of the Italian phase III SAFE trial reported in JAMA Oncology, Livi et al found that a cardioprotective strategy using ramipril and/or bisoprolol reduced the risk of myocardial dysfunction in women with nonmetastatic breast cancer receiving anthracycline-based chemotherapy....

prostate cancer

Prostate Cancer Diagnostics: Novel Approaches Are Leaving Conventional Imaging Behind

Advances in molecular imaging are having a big impact on prostate cancer management and outcomes, according to Ashesh B. Jani, MD, the James C. Kennedy Professor in Prostate Cancer, Department of Radiation Oncology at the Winship Cancer Institute of Emory University, Atlanta. Dr. Jani described his ...

covid-19

Update to NCCN: Cancer and COVID-19 Vaccination Guidance Announced

Today, the National Comprehensive Cancer Network® (NCCN®) announced significant updates to the NCCN: Cancer and COVID-19 Vaccination guidance. This is the fourth version of NCCN’s COVID-19 vaccination guide and incorporates the latest data plus recent approvals from the U.S. Food and Drug...

neuroendocrine tumors

Study Examines Cancer-Specific Mortality Among Patients With Neuroendocrine Tumors

In a new study published by Hallet et al in JNCCN—Journal of the National Comprehensive Cancer Network, among patients with neuroendocrine tumors (NETs), the risk of dying of cancer was higher than that of dying of other causes, but mortality varied by primary tumor site. According to the authors,...

cns cancers
genomics/genetics

ALK Fusion–Positive High-Grade Glioma: Response to Lorlatinib in a Single Pediatric Case

In a letter to the editor published in The New England Journal of Medicine, Bagchi et al describe the course of treatment in a 3-year-old child with an intracranial tumor and his response to therapy with the kinase inhibitor lorlatinib. Key Points Magnetic resonance imaging (MRI) of the head in a...

issues in oncology

Effects of Removing Race in the CKD-EPI Equation for Estimated Glomerular Filtration Rate

In a study reported in The Lancet Oncology, Casal et al showed that removing race as a factor in the Chronic Kidney Disease–Epidemiology Collaboration (CKD-EPI) equation for estimated glomerular filtration rate (eGFR) would result in calculation of a lower eGFR in Black patients. This might result...

myelodysplastic syndromes

Personalized Risk Prediction Model for Patients With Myelodysplastic Syndromes

As reported in the Journal of Clinical Oncology, Aziz Nazha, MD, and colleagues have developed a model for predicting the risk of disease progression for individual patients with myelodysplastic syndromes (MDS). To develop the prediction model for overall survival and leukemic transformation,...

breast cancer
immunotherapy

Update on U.S. Indication for Atezolizumab in PD-L1–Positive Metastatic Triple-Negative Breast Cancer

Genentech, a member of the Roche Group, announced that it has made the decision to voluntarily withdraw the U.S. accelerated approval for atezolizumab (Tecentriq) in combination with nab-paclitaxel for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast...

colorectal cancer
genomics/genetics

Liquid Biopsy Is Changing Colon Cancer Management

The measurement of circulating tumor DNA (ctDNA) is changing the way gastrointestinal cancers are managed, according to Bassel F. El-Rayes, MD, Professor and Vice Chair for Clinical Research in the Department of Hematology and Oncology, Emory University, and Associate Cancer Center Director,...

breast cancer
covid-19

Study Finds Drop in Breast Cancer Screening Rates in Low-Income Communities During the COVID-19 Pandemic

A new study found that during the COVID-19 pandemic, breast cancer screening rates declined among women aged 50 to 74 years at 32 community health centers that serve lower-income populations in the United States. The report, published by Stacey A. Fedewa, PhD, and colleagues in the journal Cancer,...

issues in oncology
survivorship

Two Studies Explore the Role of Primary Care Providers in Effective Cancer Care

Communication between patients and their primary care providers is key to ensuring effective cancer care, both before diagnosis and after treatment, according to two recent papers authored by University of Michigan Rogel Cancer Center researchers. Although each study analyzed different stages of...

prostate cancer

Prostate Cancer Screening Using the Stockholm3 Screening Test With MRI-Guided Biopsy

In a Swedish prostate cancer screening trial (STHLM3-MRI) reported in The Lancet Oncology, Nordström et al found that use of the Stockholm3 screening test together with magnetic resonance imaging (MRI)-guided biopsy reduced overdetection of disease while preserving the ability to detect clinically...

hematologic malignancies
lymphoma

Ixazomib/Rituximab/Dexamethasone for Relapsed or Refractory Waldenström’s Macroglobulinemia

In a phase I/II trial (HOVON124/ECWM-R2) reported in the Journal of Clinical Oncology, Kersten et al found that the combination of oral ixazomib with subcutaneous rituximab and dexamethasone showed efficacy in patients with relapsed or refractory Waldenström’s macroglobulinemia, with a manageable...

genomics/genetics

Cancer Predisposition Screening Tool for Predicting Subsequent Malignancies in Childhood Cancer Survivors

In a Canadian study reported in the Journal of Clinical Oncology, Cullinan et al found that the McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG) tool provided predictive value for risk of subsequent malignant neoplasms in childhood cancer survivors beyond risk associated with treatment...

issues in oncology
colorectal cancer

Japanese Study Examines How Intervention Encourages Screening for Colorectal Cancer Among Patients With Schizophrenia

Cancer is a leading cause of mortality in patients with mental illnesses. Although individuals with mental illnesses are equally as vulnerable to cancer as the general population, they are at a much higher risk of cancer-related mortality. Owing to a lack of early screening in most cases, such...

colorectal cancer

Antihypertensive Medications May Improve Survival Among Patients With Stage I to III Colorectal Cancer

Commonly used blood pressure drugs may improve survival for patients with colorectal cancer, a recent study published by Balkrishnan et al in Cancer Medicine suggests. After reviewing outcomes of almost 14,000 patients with colorectal cancer, researchers determined that angiotensin-converting...

cns cancers

Report Aims to Assess Contemporary Burden of Brain Tumors in the United States

A new study found that incidence rates for malignant brain and other central nervous system (CNS) tumors declined by 0.8% annually during 2008 through 2017 in the United States for all ages combined. The decline was driven by trends in adults, whereas rates have slightly increased by 0.5% to 0.7%...

breast cancer

Does Radiotherapy Reduce the Long-Term Risk of Ipsilateral Breast Recurrence in Women With DCIS Who Underwent Lumpectomy?

In an analysis of long-term outcomes from the phase III NRG/RTOG 9804 trial reported in the Journal of Clinical Oncology, Beryl McCormick, MD, and colleagues found that whole-breast irradiation vs observation was associated with reduced risk of all and invasive ipsilateral breast recurrence at 15...

immunotherapy

Profile of Adverse Events Related to PD-1 and PD-L1 Inhibitor–Based Therapy

In a systematic review and meta-analysis reported in The Lancet Oncology, Zhou et al provided a profile of treatment-related adverse events observed in clinical trials combining PD-1 or PD-L1 inhibitors with chemotherapy, targeted therapy, immunotherapy, and radiotherapy. Study Details The...

hepatobiliary cancer

FDA Approves Ivosidenib for Advanced or Metastatic IDH1-Mutated Cholangiocarcinoma

On August 25, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo), a small-molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), for adult patients with previously treated locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation as detected by an FDA-approved ...

pain management

Study Finds Evidence-Based Interventions Added to Screening Did Not Improve Cancer Pain

When added to regular screening and guidelines, evidence-based interventions implemented at the patient, health professional, and service levels did not significantly improve cancer pain, according to research led by Melanie Lovell, MBBS, PhD, Medical Head of Palliative Care at HammondCare and...

ASCO and MASCC/ISOO Publish Joint Guideline on Prevention, Treatment of Salivary Gland Hypofunction and Xerostomia

A new joint ASCO guideline offers clinicians updated evidence-based recommendations for the prevention and treatment of salivary gland hypofunction and xerostomia caused by nonsurgical cancer therapies.1 The guidance was developed together by ASCO and the Multinational Association of Supportive...

covid-19

ASCO Joins Statement Supporting Mandatory Health Employer COVID-19 Vaccination

With COVID-19 case counts rising amid the spread of the Delta variant, ASCO has joined more than 50 health-care professional societies and organizations that represent millions of workers throughout health and long-term care in calling for all health-care employers to require their employees to be...

Leland Chung, PhD, Distinguished Mentor and Urologic Oncology Research Scientist, Dies at 80

Talk to anyone who knew Leland Chung, PhD, and you’ll hear the same descriptions of the famed scientist: warm, humble, gracious, brilliant, innovative. Dr. Chung, who served as Director of the Urologic Oncology Research Program at Cedars-Sinai Cancer in Los Angeles for 12 years and was Professor in ...

breast cancer

I’m a Two-Time Breast Cancer Survivor, and the Experience Has Been Life-Altering

Even before my breast cancer diagnosis in early 2002, the year was shaping up to be life-altering for me and my family. We had moved from Seattle to Houston for a new career opportunity for my husband and were just settling into our new home when I felt a pea-sized nodule in my left breast during a ...

neuroendocrine tumors

Neuroendocrine Tumor Specialist Pamela Kunz, MD, Looks to Promote Equity in the Workforce

In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Pamela Kunz, MD, Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center. Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine...

breast cancer
immunotherapy

Sacituzumab Govitecan-hziy for Locally Advanced or Metastatic Triple-Negative Breast Cancer

On April 7, 2021, sacituzumab govitecan-hziy was granted regular approval for treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.1 Sacituzumab...

Marcus Bosenberg, MD, PhD, Named Inaugural Director of Yale Center for Immuno-Oncology

The Yale Center for Immuno-Oncology has announced the appointment of Marcus Bosenberg, MD, PhD, as its inaugural Director. Dr. Bosenberg is Professor of Dermatology, Pathology, and Immunobiology; Co-Leader of the Genomics, Genetics, and Epigenetics Program in Yale Cancer Center; contact principal...

bladder cancer
immunotherapy

Sacituzumab Govitecan-hziy for Locally Advanced or Metastatic Urothelial Cancer

On April 13, 2021, sacituzumab govitecan-hziy was granted accelerated approval to treat patients with locally advanced or metastatic urothelial cancer who had received platinum-containing chemotherapy and either a PD-1 or a PD-L1 inhibitor.1 Supporting Efficacy Data Approval was based on findings...

hematologic malignancies
symptom management

Belumosudil for Chronic Graft-vs-Host Disease

On July 16, 2021, belumosudil, an inhibitor of Rho-associated coiled-coil kinase 2, was approved for the treatment of adult and pediatric patients 12 years and older with chronic graft-vs-host disease after the failure of at least two prior lines of systemic therapy.1 Supporting Efficacy Data...

lung cancer

High Prevalence of Previously Undiagnosed Emphysema Among Individuals Undergoing Low-Dose CT Screening for Lung Cancer

In a prospective cohort study reported in Clinical Imaging, David Steiger, MD, of the Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, in New York, and colleagues in the International Early Lung Cancer Action Program (I-ELCAP) identified emphysema in ...

breast cancer

New Guideline Provides Clarity on Timing, Treatment of Axilla in Early-Stage Breast Cancer

ASCO and Ontario Health (Cancer Care Ontario) have collaborated to release a new clinical practice guideline on the management of the axilla in early-stage breast cancer.1 “A lot has changed in the past several years with regard to de-escalating the amount of treatment women are offered in the...

multiple myeloma

Isatuximab-irfc in Relapsed or Refractory Multiple Myeloma

On March 31, 2021, the anti-CD38 monoclonal antibody isatuximab-irfc was approved for use in combination with carfilzomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.1 Supporting Efficacy Data...

Heather Wakelee, MD, FASCO, Honored With the 2021 Bonnie J. Addario Lectureship Award

GO2 Foundation for Lung Cancer (GO2 Foundation) presented Heather Wakelee, MD, FASCO, with the 2021 Bonnie J. Addario Lectureship Award at the Physicians’ Education Resource 22nd Annual International Lung Cancer Congress on July 30 in Huntington Beach, California. Dr. Wakelee is Professor of...

Vanderbilt University Appoints Karen Winkfield, MD, PhD, Professor of Radiation Oncology

Karen Winkfield, MD, PhD, Executive Director, Meharry-Vanderbilt Alliance, and Ingram Professor of Cancer Research, was recently promoted to Professor of Radiation Oncology at Vanderbilt University Medical Center (VUMC). “Grateful to those who paved the way,” said Dr. Winkfield on Twitter, noting...

Winette van der Graaf, MD, PhD, Named EORTC President-Elect 2021–2024

The European Organisation for Research and Treatment of Cancer (EORTC) has announced that Winette van der Graaf, MD, PhD, will be EORTC President-Elect 2021–2024. Bertrand Tombal, MD, PhD, will remain EORTC President until March 11, 2022, when the EORTC celebrates its 60th anniversary. Dr. van...

global cancer care
breast cancer

Historic, Present, and Future Perspectives on Breast Cancer in Egypt

Breast cancer is the most frequently diagnosed cancer among women around the world, making it a significant public health problem.1 The disease affects both men and women, although it is rare in men, accounting for just 1% of all breast cancer diagnoses in the United States and less than 0.1% of...

lung cancer

Low-Dose CT Screening for Lung Cancer and the Incidental Findings That May Improve Future Health

Every interaction with patients is an opportunity to change the course of their lives. In the context of screening for disease, every encounter is an opportunity to detect the precursors or early changes that signal early pathophysiology. Smoking status and age are the factors that currently...

lymphoma

Axicabtagene Ciloleucel Improves Multiple Clinical Endpoints in Relapsed Follicular Lymphoma

For the treatment of relapsed or refractory follicular lymphoma, updated data from the ZUMA-5 trial, as compared with the findings of the external control cohort of SCHOLAR-5, showed substantial improvement in all key clinical endpoints with axicabtagene ciloleucel, ZUMA-5 investigators reported in ...

hematologic malignancies
head and neck cancer
gynecologic cancers
immunotherapy
symptom management

FDA Pipeline: Reviews for Agents in Acute Graft-vs-Host Disease, Nasopharyngeal and Ovarian Cancers

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to an agent for the prevention of acute graft-vs-host disease; Breakthrough Therapy designation to an anti–PD-1 monoclonal antibody for the treatment of metastatic nasopharyngeal carcinoma; and Fast Track designation to a ...

Advertisement

Advertisement




Advertisement